Edition:
United States

Carmat SA (ALCAR.PA)

ALCAR.PA on Paris Stock Exchange

22.44EUR
--
Change (% chg)

-- (--)
Prev Close
€22.44
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,658
52-wk High
€40.06
52-wk Low
€21.13

Chart for

About

Carmat SAS is a France-based Company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart and which is hydraulically activated. The Company formed a network of partnerships with hospitals and various scientific... (more)

Overall

Beta: 0.77
Market Cap(Mil.): €135.91
Shares Outstanding(Mil.): 5.93
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.48 16.83
EPS (TTM): -- -- --
ROI: -- 13.80 10.92
ROE: -- 16.64 14.52

BRIEF-Carmat expands pivotal study internationally

* CARMAT EXPANDS ITS PIVOTAL STUDY INTERNATIONALLY, IN LINE WITH ITS CLINICAL STRATEGY AND CE MARKING PROCESS

Oct 05 2017

BRIEF-Carmat reports H1 operating expenses of 14.7 million euros

* ‍CONFIRMATION OF OBJECTIVE OF COMPLETING PIVOTAL STUDY AT END OF 2018​

Sep 26 2017

French implant maker Carmat pins hopes on low energy heart

PARIS Artificial heart maker Carmat is hoping a more energy-efficient implant and the appointment of a production chief can help it overcome recent failures at the French firm.

Jul 05 2017

Carmat buoyed by approval to resume artificial heart trial

Artificial heart maker Carmat has obtained approval from France's national drugs agency (ANSM) to resume a heart implant trial, sending the company's shares more than one fifth higher on Wednesday.

May 03 2017

UPDATE 2-Carmat buoyed by approval to resume artificial heart trial

May 3 Artificial heart maker Carmat has obtained approval from France's national drugs agency (ANSM) to resume a heart implant trial, sending the company's shares more than one fifth higher on Wednesday.

May 03 2017

Carmat gets approval to resume artificial heart implants trial

May 2 Artificial heart maker Carmat has obtained approval from France's national drugs agency (ANSM) to resume heart implant trials, the company said on Tuesday.

May 02 2017

Earnings vs. Estimates